Jayantilal Bhimani, MD
Internal Medicine · Cleveland, OHNPI 1619943388
Payments from drug & device makers
Across 481 payments — averaging $26.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Johnson & Johnson$623
- Lilly USA, LLC$622
- AstraZeneca$598
- AbbVie$580
- Bayer$507
- plus $5K from 48 others
What the payments were for
- Consulting fees$3,97532%
- Food & beverage$8,46967%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$1,620
- Victoza$1,485
- iTIND System$138
- XARELTO$112
- Kerendia$104
How this compares
$12,552 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,593 | $452,893 |
| Invega SustennaPaliperidone Palmitate | 85 | $274,428 |
| IngrezzaValbenazine Tosylate | 29 | $239,739 |
| XareltoRivaroxaban | 352 | $94,106 |
| JardianceEmpagliflozin | 264 | $91,736 |
| NuedextaDextromethorphan Hbr/Quinidine | 90 | $80,743 |
| TrulicityDulaglutide | 109 | $72,151 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $72,150 |
| XifaxanRifaximin | 50 | $65,234 |
| TivicayDolutegravir Sodium | 25 | $61,625 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $58,770 |
| FarxigaDapagliflozin Propanediol | 204 | $57,842 |
| AristadaAripiprazole Lauroxil | 18 | $54,100 |
| RexultiBrexpiprazole | 66 | $53,683 |
| EntrestoSacubitril/Valsartan | 150 | $42,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $243 | $452,8931,593 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $623 | $368,534437 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $178 | $239,73929 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $248 | $120,935238 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $43 | $118,957315 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $39 | $80,74390 claims |
| AstraZenecaFarxiga, Lokelma | $598 | $76,267258 claims |
| Lilly USA, LLCTrulicity | $622 | $72,151109 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $43 | $65,23450 claims |
| GileadBiktarvy | $62 | $58,77014 claims |
| Alkermes, Inc.Aristada | $360 | $54,10018 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $324 | $53,68366 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cleveland
- Vadim KoshkinCleveland$6.1M
- Emily LittlejohnCleveland$885K
- Marina MagreyCleveland$856K
- Pushkar KanadeCleveland$753K
- Cyrus HarrisCleveland$726K
- Ila TamaskarCleveland$721K
- Amar KrishnaswamyCleveland$552K
- Albree Tower-RaderCleveland$522K
- Adriano TonelliCleveland$464K
- Mahboob RahmanCleveland$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.